Company news

Precision BioSciences, Inc. news in 2021

Precision BioSciences, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Precision BioSciences Completes Spin-Out of Elo Life Systems

December 20, 2021

Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline

December 10, 2021

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

December 5, 2021

Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors

November 7, 2021

Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology

November 3, 2021

Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021

November 2, 2021

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

September 26, 2021

Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

September 26, 2021

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

September 8, 2021

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

September 8, 2021

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

September 1, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

August 24, 2021

Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 11, 2021

Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

August 4, 2021

Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma

June 30, 2021

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

May 31, 2021

Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

May 26, 2021

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

May 12, 2021

Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

May 5, 2021

Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting

April 26, 2021

Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

April 14, 2021

Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

April 11, 2021

Precision BioSciences Announces CEO Transition Plan

April 5, 2021

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

March 17, 2021

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

March 11, 2021

Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

February 18, 2021

Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

January 24, 2021

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

January 18, 2021

Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company

January 6, 2021

Decks in 2021